Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
2
users have commented on this narrative
43
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
0
users have commented on this narrative
16
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.3% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
16
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Ultragenyx Pharmaceutical
AN
AnalystHighTarget
Consensus Narrative from 20 Analysts
Advanced Gene Therapies Will Drive Global Rare Disease Growth
Key Takeaways Rapid international expansion, innovative therapies, and strong patient outcomes position Ultragenyx for accelerated growth and greater market share than current expectations suggest. Scalable manufacturing, operational discipline, and advanced diagnostics are set to drive margin expansion and unlock a larger addressable market in rare diseases.
View narrative
US$128.00
FV
76.8% undervalued
intrinsic discount
46.58%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 23 hours ago
author updated this narrative
Sweetgreen
AN
AnalystHighTarget
Consensus Narrative from 12 Analysts
Emerging Automation Will Drive Healthy, Sustainable Dining Trends
Key Takeaways Infinite Kitchens and new store formats are driving improved unit economics, operational consistency, and accelerating future margin and sales growth. Enhanced digital rewards and menu innovation are fueling rapid customer engagement, positioning Sweetgreen to capture greater market share amid rising demand for health-forward dining.
View narrative
US$21.00
FV
56.2% undervalued
intrinsic discount
19.48%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 23 hours ago
author updated this narrative
Exact Sciences
AN
AnalystConsensusTarget
Consensus Narrative from 23 Analysts
Humana, Centene And Medicare Coverage Will Increase Screening Access
Key Takeaways Broadening payer coverage and demographic trends toward an older population are positioning Exact Sciences for sustained and expanding revenue opportunities from core and new product offerings. Cost optimization initiatives, operational scale, and tech-driven efficiency improvements are enhancing profitability while product portfolio diversification increases market competitiveness and revenue streams.
View narrative
US$62.97
FV
27.6% undervalued
intrinsic discount
11.62%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
31
users have followed this narrative
2 days ago
author updated this narrative
Flutter Entertainment
AN
AnalystConsensusTarget
Consensus Narrative from 25 Analysts
Brazil And US Markets Will Unlock iGaming Opportunities
Key Takeaways Expansion in new markets, product innovation, and platform integration are expected to drive user engagement, market share, and sustained earnings growth. Structural cost efficiencies and deeper iGaming penetration should enhance margins, free cash flow, and shareholder returns over the long term.
View narrative
US$343.11
FV
14.5% undervalued
intrinsic discount
16.42%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
12
users have followed this narrative
2 days ago
author updated this narrative
argenx
AN
AnalystConsensusTarget
Consensus Narrative from 14 Analysts
Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities
Key Takeaways Broadening indications and effective global expansion for Vyvgart, alongside pipeline progress, are driving strong, sustained revenue and margin growth. Strategic partnerships and advances in disease targeting are expanding market opportunities and operational efficiencies, supporting long-term growth potential.
View narrative
€694.75
FV
20.3% undervalued
intrinsic discount
30.08%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
20
users have followed this narrative
2 days ago
author updated this narrative
GeneDx Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
Expanding Pediatric Genomics Will Transform Rare Disease Diagnostics
Key Takeaways Accelerating adoption of genomics in pediatrics and enhanced AI platforms drive growth, efficiency, and margin improvement while reinforcing competitive advantage. Increasing reimbursement, enriched rare disease datasets, and global biopharma partnerships support recurring revenues, premium pricing, and high barriers to entry.
View narrative
US$115.29
FV
9.6% overvalued
intrinsic discount
19.50%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
19
users have followed this narrative
2 days ago
author updated this narrative
PROCEPT BioRobotics
AN
AnalystHighTarget
Consensus Narrative from 9 Analysts
Aging Population And Robotic Advances Will Unlock Urologic Potential
Key Takeaways Accelerated adoption, streamlined reimbursement, and demographic trends are expected to drive stronger-than-expected revenue growth, operating leverage, and recurring handpiece demand. Expansion into new procedure categories and global markets, backed by clinical trials, strong cash reserves, and experienced leadership, positions the company for substantial long-term upside.
View narrative
US$85.00
FV
51.1% undervalued
intrinsic discount
30.82%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 23 hours ago
author updated this narrative
C3.ai
AN
AnalystHighTarget
Consensus Narrative from 13 Analysts
Generative AI And Digital Transformation Will Reshape Markets
Key Takeaways Expanding partnerships and contract renewals position C3.ai for outsized revenue growth, stronger sales efficiency, and greater earnings visibility across core and emerging sectors. Early leadership in generative and Agentic AI plus broad adoption in critical industries establish C3.ai as a default, long-term platform standard for enterprise and government AI needs.
View narrative
US$36.67
FV
51.3% undervalued
intrinsic discount
20.66%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
about 23 hours ago
author updated this narrative
Liberty Global
AN
AnalystHighTarget
Consensus Narrative from 15 Analysts
Fiber Upgrades And Digital Convergence Will Fuel Secular Demand
Key Takeaways Spin-outs, asset separations, and innovative structures are set to rapidly unlock hidden value and drive substantial upside in valuation and cash flow. Early digital infrastructure investments, advanced technology upgrades, and proactive retention strategies position Liberty for higher revenue growth, margin expansion, and industry leadership.
View narrative
US$27.80
FV
58.5% undervalued
intrinsic discount
3.18%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 23 hours ago
author updated this narrative
Value any company in seconds
Popular companies